Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

OBJECTIVE: New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required....

Descripción completa

Detalles Bibliográficos
Autores principales: Acibuca, Aynur, Sezer, Ahmet, Yilmaz, Mustafa, Sumbul, Ahmet Taner, Demircan, Senol, Muderrisoglu, Ibrahim Haldun, Ozyilkan, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Retrospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671676/
https://www.ncbi.nlm.nih.gov/pubmed/34898302
http://dx.doi.org/10.1177/03000605211053755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671676/
https://www.ncbi.nlm.nih.gov/pubmed/34898302
http://dx.doi.org/10.1177/03000605211053755

Ejemplares similares